This guidance document comes after AllTrials, an international initiative, launched a tracking tool in February 2018 that publicly discloses which research entities have not reported data from clinical trials.
Last month, the FDA published a draft guidance document relating to potential fines that may be incurred if submitters of data and trial information on clinicaltrials.gov either do not report clinical trial results, or misreport findings.
The document, “Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank,” explains that under section 303(f)(3) of the Federal Food, Drug and Cosmetic Act (FD&C Act), the FDA is authorized to assess civil money penalties against responsible parties and/or submitters of applications for drug products, biologics, and devices.
The guidance also answered some general questions, such as how the FDA intends to identify whether an organization or someone has failed to submit required clinical trial registration and/or results to the data bank or submitted false information. The FDA plans to identify such violations through evidence collected during inspections, as well as through complaints received by the agency.
If the agency has deemed that a party has failed to comply with regulation, it “intends to send the responsible party a Preliminary Notice of Noncompliance (Pre-Notice) Letter, which describes the potential violation and requests that the responsible party review the record in the ClinicalTrials.gov data bank and make any necessary corrections within 30 days,” read the document. If the violation has not been addressed in the 30 days, the agency will then send a Notice of Noncompliance, which allows the party an additional 30 days to remedy the situation.
Should a civil money penalty be assessed, the statutory maximum penalties under the FD&C Act are no more than $10,000 for all violations adjudicated in a single proceeding. In addition, if a violation is not corrected within the 30 days following notification of a violation, an organization can be fined up to, but not more than, $10,000 per day the violation continues.
This guidance document comes after AllTrials, an international initiative, launched a tracking tool in February 2018 that publicly discloses which research entities have not reported data from clinical trials.
Included in the announcement of the initiative was an open letter to FDA Commissioner Scott Gottlieb, MD, that noted that the FDA has the power to sanction such violators and institute fines against clinical trial sponsors that fail to report trial results, and urged the Commissioner to do just that.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.